Echo touts positive results for transdermal system; pSivida gets patent for micro needle;

 @DamianFierce: One U.K. company is developing a chocolate-based drug delivery platform, and NIH has taken notice. Report | Follow @DamianFierce

> During the weekend's American Diabetes Association gathering, Echo Therapeutics ($ECTE) unveiled trial data of its Symphony tCGM glucose monitor--which uses the company's skin-permeation platform--demonstrating the device's accuracy. More

> Biodel ($BIOD) has licensed Aegis Therapeutics' transmucosal absorption tech Intravail to develop glucagon treatments for diabetics. News

> pSivida, maker of drug-emitting back-of-the-eye implants, secured a patent for a new inserter the company says will allow doctors to get its devices into patients with far less force. Story

> Drug delivery CRO Particle Sciences has expanded its offerings to include polymer-based films that can deliver liquid-formulation drugs. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.